{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:06:29Z","timestamp":1787061989168,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ijantimicag.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T13:45:13Z","timestamp":1498571113000},"page":"303-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new"],"prefix":"10.1016","volume":"50","author":[{"given":"Michael Z.","family":"David","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Dryden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Tattevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrmicro2200","article-title":"Waves of resistance: Staphylococcus aureus in the antibiotic era","volume":"7","author":"Chambers","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fpubh.2014.00217","article-title":"Vancomycin revisited\u201460 years later","volume":"2","author":"Rubinstein","year":"2014","journal-title":"Front Public Health"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0020","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1172\/JCI68834","article-title":"Mechanisms of vancomycin resistance in Staphylococcus aureus","volume":"124","author":"Gardete","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0025","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1172\/JCI18535","article-title":"Antimicrobial resistance: the example of Staphylococcus aureus","volume":"111","author":"Lowy","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/CE.S33430","article-title":"An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy","volume":"7","author":"Watkins","year":"2012","journal-title":"Core Evid"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jac\/dkh088","article-title":"Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections","volume":"53","author":"Wilcox","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2013.05.005","article-title":"Daptomycin: the role of high-dose and combination therapy for Gram-positive infections","volume":"42","author":"Gould","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2017.05.006_bib0045","first-page":"ii3","article-title":"Tigecycline: an antibiotic for the twenty-first century","volume":"68","author":"Dryden","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0050","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13063-016-1295-3","article-title":"CAMERA2\u2014combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial","volume":"17","author":"Tong","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0055","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0060","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0065","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/phar.1337","article-title":"Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0070","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1128\/AAC.00859-08","article-title":"In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains","volume":"52","author":"Shaw","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0075","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1128\/AAC.00663-10","article-title":"Structure\u2013activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations","volume":"54","author":"Locke","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0080","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12941-014-0046-0","article-title":"Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone","volume":"13","author":"Zurenko","year":"2014","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0085","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2014.12.008","article-title":"Linezolid-resistant staphylococcal bacteraemia: a multicentre case\u2013case\u2013control study in Italy","volume":"45","author":"Russo","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0090","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3343\/alm.2015.35.5.523","article-title":"In vitro activity of tedizolid against Gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter study","volume":"35","author":"Lee","year":"2015","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0095","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jac\/dkv302","article-title":"Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid","volume":"71","author":"Barber","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0100","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/jac\/dkw206","article-title":"Characterization of the haematological profile of 21 days of tedizolid in healthy subjects","volume":"71","author":"Lodise","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0105","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/cid\/civ311","article-title":"Oritavancin: a long-half-life lipoglycopeptide","volume":"61","author":"Saravolatz","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0110","first-page":"189","article-title":"Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections","volume":"8","author":"Mitra","year":"2015","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0115","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0120","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0125","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ijantimicag.2015.08.014","article-title":"In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011\u20132014","volume":"46","author":"Biedenbach","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0130","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1403789","article-title":"Clindamycin versus trimethoprim\u2013sulfamethoxazole for uncomplicated skin infections","volume":"372","author":"Miller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0135","first-page":"3","article-title":"Oritavancin (Orbactiv) for skin and skin structure infections","volume":"57","year":"2015","journal-title":"Med Lett Drugs Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2017.05.006_bib0140","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure, and activity in vitro and in vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","article-title":"Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections","volume":"4","author":"Smith","year":"2015","journal-title":"Infect Dis Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2017.05.006_bib0150","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/jac\/dki008","article-title":"Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide","volume":"55","author":"Dorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0155","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0160","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0165","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0170","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0175","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-015-0374-9","article-title":"Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies","volume":"39","author":"Dunne","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0180","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.48.3.1061-1064.2004","article-title":"Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin","volume":"48","author":"Lefort","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0185","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijantimicag.2013.05.019","article-title":"Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model","volume":"42","author":"Baldoni","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0190","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1586\/eri.12.112","article-title":"Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA","volume":"10","author":"Garrison","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0195","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0200","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.05738-11","article-title":"CANVAS 1 and 2: analysis of clinical response at Day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections","volume":"56","author":"Friedland","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0205","first-page":"149","article-title":"Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections","volume":"8","author":"Goodman","year":"2012","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0210","series-title":"A phase III trial of ceftaroline fosamil 600\u2009mg q8h versus vancomycin plus aztreonam in patients with cSSTI with systemic inflammatory response or underlying comorbidities","author":"Dryden","year":"2015"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0215","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1128\/AAC.00817-12","article-title":"Activity of ceftaroline\u2013avibactam tested against Gram-negative organism populations, including strains expressing one or more \u03b2-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types","volume":"56","author":"Castanheira","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0220","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0230","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/QCO.0000000000000142","article-title":"Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection?","volume":"28","author":"Dryden","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0235","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1128\/AAC.03622-14","article-title":"PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates","volume":"58","author":"Long","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0240","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/jac\/dkv124","article-title":"Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia","volume":"70","author":"Mubarak","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149541","article-title":"Whole-genome sequencing of methicillin-resistant Staphylococcus aureus resistant to fifth-generation cephalosporins reveals potential non-mecA mechanisms of resistance","volume":"11","author":"Greninger","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.05.006_bib0250","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T02:56:06Z","timestamp":1569552966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917301954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0924857917301954"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.05.006","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}